secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profound Medical Corp. (PROF)
CIK:        0001628808
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001171843-26-001362
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Profound Medical Q4 revenue $6M (+43% YoY), net loss $8.2M; installed base 78 TULSA-PRO
--------------------------------------------------------------------------------

- Q4 revenue record $6.0M (+43% YoY); net loss $8.2M ($0.27/sh) vs $4.9M loss year ago.
- FY2025 revenue $16.1M (up from $10.7M); net loss $42.6M ($1.41/sh) vs $27.8M loss.
- TULSA-PRO installed base 78, pipeline 110; expects ~120 installs by end of 2026.
- Dec 2025 financing: $36M US offering + $6.45M Canadian private placement; cash $59.7M.
- Board change: Kris Shah resigns, Frank Baylis appointed; Baylis co-founded Baylis Medical (sold for $1.75B).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326001362/0001171843-26-001362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326001362/f8k_030526.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-001362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer